US Patent 6,962,908: Estradiol Acetate Solid Dosage Patent Scope, Expiration, and Generic Risk

US Patent 6,962,908 protects low-dose oral solid dosage forms containing 17β-estradiol-3-acetate, also called estradiol acetate, with controlled moisture and acetic acid as an ester-hydrolysis inhibitor. The broadest claim requires all of those elements in the same dosage unit.

The patent issued on November 8, 2005, from an application claiming priority to a 2001 filing. Its standard patent term expired in 2022, subject to any patent-term adjustment or terminal-disclaimer information shown in the USPTO file history. The patent therefore does not present a current blocking patent to an FDA-approved generic applicant, although its technical teachings remain relevant to formulation development and freedom-to-operate analysis.

What does US Patent 6,962,908 protect?

The patent protects a pharmaceutical solid dosage unit for oral administration to a human female containing:

17β-estradiol-3-acetate;
A therapeutically effective amount equivalent to about 0.1 mg to about 10 mg of estradiol;
A pharmaceutically acceptable carrier;
Total dosage-unit moisture of 8% or less; and
Acetic acid as an inhibitor of ester hydrolysis.

Claim 1 is the independent product claim. The remaining claims narrow that product by reducing moisture, adding other steroids, specifying progestational steroids, identifying a granulation process, and limiting the dosage form.

The patent is directed to chemical stability. Estradiol acetate is an ester that can hydrolyze to estradiol under unfavorable moisture conditions. The claims use reduced moisture and acetic acid to limit degradation in a solid oral product.

Claim architecture

Claim	Type	Additional limitation	Scope
1	Independent composition/product claim	Estradiol acetate, 0.1-10 mg estradiol equivalent, moisture ≤8%, acetic acid, carrier	Broadest claimed formulation
2	Dependent	Moisture below 5%	Narrower moisture specification
3	Dependent	One or more additional steroids	Combination steroid product
4	Dependent	Additional steroids have progestational activity	Estradiol acetate plus progestin
5	Dependent	Prepared by granulation	Process-defined product limitation
6	Dependent	Tablet, capsule, powder, lozenge, or troche	Enumerated solid dosage forms
7	Dependent	Tablet or capsule	Narrowest practical commercial forms

How should claim 1 be construed?

Claim 1 is a combination claim. A product generally must satisfy every limitation to fall within its literal scope.

A potentially infringing product would need to contain estradiol acetate rather than ordinary estradiol, use a solid oral dosage unit, fall within the claimed dose range, have no more than 8% moisture, and contain acetic acid functioning as a pharmaceutically acceptable ester-hydrolysis inhibitor.

The claim does not cover every estradiol product. It does not, on its face, cover:

A transdermal patch, cream, gel, vaginal ring, injection, or implant;
A liquid oral formulation;
A solid product containing estradiol but not estradiol acetate;
A product with more than 8% moisture;
A product using a different stabilizer without acetic acid;
A product outside the claimed estradiol-equivalent dose range.

The phrase “as estradiol equivalent” is important. Estradiol acetate has a molecular weight different from estradiol. The claim measures the active amount by the corresponding estradiol quantity rather than simply stating the mass of estradiol acetate.

What is the scope of the moisture limitation?

Claim 1 requires moisture of 8% or less. Claim 2 narrows that requirement to below 5%.

The patent does not merely require a dry manufacturing environment. The wording applies to the dosage unit. A product developer would therefore need to assess the finished product’s moisture content using the relevant analytical method and at the relevant point in the product lifecycle.

The moisture limitation creates several enforcement and design-around issues:

A formulation at 4.9% moisture may fall within claims 1 and 2.
A formulation at 6% moisture may fall within claim 1 but not claim 2.
A formulation above 8% may avoid literal infringement of claims 1 and 2.
A product initially below the threshold but later exceeding it may raise questions concerning testing conditions, product identity, and claim interpretation.
Water activity, residual solvent, loss on drying, and Karl Fischer water content may not produce identical results.

The patent’s commercial value was tied to controlling degradation in a low-dose oral ester formulation. The numerical moisture limits are also potential points of invalidity or non-infringement analysis if prior art disclosed stable estradiol acetate tablets with comparable moisture levels.

What does the acetic acid limitation require?

Claim 1 requires “a pharmaceutically acceptable inhibitor of ester hydrolysis that is acetic acid.” The claim does not broadly cover all hydrolysis inhibitors. It specifically identifies acetic acid.

This limitation creates a meaningful distinction between:

Acetic acid-containing estradiol acetate formulations;
Formulations stabilized with citric acid, tartaric acid, fumaric acid, or another acid;
Formulations relying only on low moisture;
Formulations using a different excipient that changes local pH or water activity.

The claim also requires acetic acid to function as an inhibitor of ester hydrolysis. Merely detecting incidental acetate or acetic acid contamination would not necessarily establish that the ingredient is present as a formulation stabilizer. The amount, formulation role, and product composition would be relevant in an infringement analysis.

Which dosage forms fall within claims 6 and 7?

Claim 6 covers a tablet, capsule, powder, lozenge, or troche. Claim 7 limits the dosage unit to a tablet or capsule.

The patent is therefore strongest against oral solid products that use estradiol acetate in conventional unit-dose forms. Claim 7 is particularly relevant to commercial oral products because tablets and capsules are the most likely dosage forms for an FDA-approved systemic hormone product.

The claims do not expressly require a specific excipient system, dissolution profile, release profile, tablet hardness, capsule shell, or manufacturing equipment. A product could use different fillers, binders, lubricants, disintegrants, coatings, or capsule materials and still raise a claim issue if it satisfies the independent limitations.

How do claims 3 and 4 affect combination products?

Claims 3 and 4 extend the estate to combination products.

Claim 3 covers a dosage unit containing estradiol acetate and one or more additional steroids. Claim 4 narrows that category to steroids with progestational activity, such as a progestin used to counterbalance estrogen-related endometrial stimulation in a hormone replacement product.

These claims could be relevant to:

Estradiol acetate plus a progestin;
Fixed-dose oral hormone replacement products;
Tablets or capsules containing estrogen and progestational steroid components;
Products marketed for postmenopausal hormone therapy.

They do not necessarily cover every estrogen-progestin product. The estrogen component must be 17β-estradiol-3-acetate, and the base claim’s moisture, dose, carrier, and acetic-acid requirements remain applicable.

Products containing estradiol rather than estradiol acetate, including many conventional estradiol/progestin products, are structurally different from the claimed combination.

What is the patent expiration date?

US 6,962,908 timeline

Event	Date
Earliest priority period	2001
US application filing period	2002
Patent issued	November 8, 2005
Standard 20-year patent term	2022
Current status	Expired by ordinary term, based on the priority and filing history

For a US utility patent governed by the modern 20-year term, expiration is generally calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimer, patent-term extension, and other statutory provisions (35 U.S.C. § 154).

The patent’s expiration removes the principal patent barrier created by US 6,962,908. A current applicant would not ordinarily face a Paragraph IV certification directed to this patent unless the patent remained listed in a relevant Orange Book record, which would be unusual after expiration.

What was the FDA and Orange Book relevance?

The patent is associated with the oral estradiol acetate product Femtrace, an estradiol acetate hormone replacement product marketed in the United States. FDA records identify Femtrace under NDA 021405. The product was approved in multiple low-dose strengths, including 0.45 mg and 0.9 mg estradiol-equivalent presentations, according to FDA labeling and product databases.

Regulatory relevance

Regulatory issue	Assessment
Active ingredient	Estradiol acetate
Route	Oral
Dosage form	Solid oral dosage form
Product category	Estrogen hormone replacement therapy
NDA	021405, associated with Femtrace
Patent relevance	Formulation and dosage-unit stability
Current patent barrier	US 6,962,908 has reached its ordinary term

FDA approval does not establish patent validity or infringement. Orange Book listing reflects the sponsor’s patent certification framework and does not independently adjudicate the patent’s enforceability.

The product’s regulatory history also matters because a generic applicant would need to determine whether the reference product, listed patents, exclusivity periods, and current marketing status support an ANDA pathway. A generic estradiol acetate product may face formulation and bioequivalence issues even after patent expiration.

Were Paragraph IV challenges possible?

While US 6,962,908 was unexpired and listed for a qualifying reference product, an ANDA applicant could have addressed it through a Paragraph IV certification asserting that the patent was invalid, unenforceable, or would not be infringed.

The relevant statutory consequences would have included:

Notice to the patent owner and NDA holder;
Potential 45-day period for filing an infringement action;
A possible 30-month stay of approval under the Hatch-Waxman framework;
Litigation over claim construction, written description, enablement, anticipation, obviousness, and infringement.

The claim set would have offered several potential litigation issues:

Whether prior art disclosed estradiol acetate in a solid oral dosage unit.
Whether prior art disclosed moisture at 8% or below.
Whether acetic acid was known or obvious as an ester-hydrolysis inhibitor.
Whether the claimed dose range was supported and non-obvious.
Whether a proposed generic product contained acetic acid in the claimed functional role.
Whether the finished dosage unit met the moisture limitation.

Because the patent has expired, a new Paragraph IV challenge directed solely to US 6,962,908 would not normally provide a current launch advantage. The commercial question has shifted from patent validity to formulation development, regulatory approval, manufacturing scale-up, and any surviving patent or exclusivity rights in the relevant product record.

What other patents and exclusivity rights matter?

The competitive patent landscape includes several distinct categories.

Formulation patents

These may claim:

Low-moisture estradiol acetate tablets or capsules;
Acid-stabilized ester formulations;
Particular granulation methods;
Specific excipient ratios;
Controlled-release or immediate-release profiles;
Packaging systems that limit moisture uptake.

US 6,962,908 is most directly relevant to this category.

Method-of-use patents

A separate patent may cover using estrogen therapy for:

Vasomotor symptoms;
Vulvar or vaginal atrophy;
Osteoporosis prevention;
Menopausal hormone replacement;
Combination estrogen-progestin treatment.

US 6,962,908 is a dosage-unit composition patent, not a broad therapeutic method claim. A product can avoid this patent while still implicating a separate method-of-use patent.

Manufacturing and process patents

Claim 5 adds granulation to the claimed product. It may be relevant to a formulation made by wet or dry granulation, depending on the patent’s specification and the meaning given to “granulation method.”

A manufacturer using direct compression could potentially avoid the literal scope of claim 5, but it would still need to evaluate claims 1, 2, 6, and 7. Process differences do not avoid the independent product claim if the final dosage unit satisfies all of its limitations.

Regulatory exclusivity

FDA exclusivity is separate from patent protection. For an older small-molecule hormone product, any original three-year new clinical investigation exclusivity would have expired long before the patent term ended. Orphan-drug exclusivity is not ordinarily associated with standard systemic menopausal estrogen replacement products.

How strong was the patent estate?

The estate was commercially focused but technically narrow.

Strengths

It targeted the specific active ingredient used in an approved oral product.
It combined composition, dose, moisture, and stabilizer limitations.
Dependent claims covered tablets, capsules, combination steroids, and granulation.
The moisture and acetic-acid limitations addressed a concrete stability problem.

Weaknesses

The independent claim required multiple narrow elements.
Products using estradiol instead of estradiol acetate were outside the claim’s chemical scope.
Products using another stabilizer could avoid the acetic-acid limitation.
Products exceeding the moisture threshold could avoid literal infringement.
The patent term has expired.
Claim 5 is limited to a granulation method and does not independently protect all manufacturing routes.

The patent was more valuable as a barrier to a chemically matched estradiol acetate generic than as a barrier to the broader estrogen replacement market.

What generic launch scenarios exist?

Scenario 1: Estradiol acetate tablet matching the reference formulation

This would have presented the highest historical infringement risk because it could satisfy the active ingredient, dose, dosage-form, moisture, and acetic-acid limitations.

Scenario 2: Estradiol acetate capsule using a different stabilizer

This could avoid the acetic-acid limitation if the product did not contain acetic acid and no equivalent infringement theory applied. The product would still require evaluation against other patents.

Scenario 3: Estradiol tablet rather than estradiol acetate

This is a distinct active ingredient and would generally avoid the literal scope of US 6,962,908. It would not necessarily be therapeutically or pharmaceutically interchangeable with an estradiol acetate reference product without FDA-specific approval and bioequivalence support.

Scenario 4: Estradiol acetate product above 8% moisture

This could avoid claims 1 and 2 if the moisture measurement and product composition were established. It could create stability, shelf-life, and regulatory problems.

Scenario 5: Estradiol acetate plus progestin

This would require review of claims 1, 3, and 4, as well as any separate combination-product patents and method-of-use patents.

What is the geographic coverage?

US 6,962,908 provides rights only in the United States. Foreign protection would depend on separate national or regional family members, such as European, Canadian, Australian, or Japanese counterparts. The US expiration date does not determine foreign expiration dates, although related family members commonly share a comparable priority date and may have expired under their respective national laws.

A global freedom-to-operate review must therefore separate:

US patent status;
European Patent Office and national validation status;
Canadian patent status;
Japanese patent status;
Australian patent status;
Regulatory exclusivity in each market;
Product-specific formulation and manufacturing patents.

No US patent right can directly block manufacture, sale, or importation outside the United States.

Key Takeaways

US 6,962,908 claims oral solid dosage units containing 17β-estradiol-3-acetate.
Claim 1 requires moisture of 8% or less and acetic acid as an ester-hydrolysis inhibitor.
Claim 2 narrows moisture to below 5%.
Claims 3 and 4 cover additional steroids, including progestational steroids.
Claims 5 through 7 address granulation and specific solid dosage forms.
The patent was closely aligned with oral estradiol acetate products such as Femtrace.
Its ordinary US patent term expired in 2022.
The estate was narrow but potentially meaningful against a chemically matched tablet or capsule.
Generic developers can design around individual limitations through active-ingredient selection, stabilizer selection, moisture control, dosage form, or manufacturing method.
Current commercial exposure depends more on regulatory approval, formulation performance, manufacturing know-how, and any separate surviving patent rights than on US 6,962,908 itself.

FAQs About US Patent 6,962,908

Does US 6,962,908 cover ordinary estradiol tablets?

No. The claims require 17β-estradiol-3-acetate. A product containing estradiol rather than estradiol acetate is chemically distinct and would generally fall outside the literal scope of the claims.

Does the patent cover an estradiol acetate transdermal patch?

No. The claims require a solid dosage unit for oral administration. A patch is a different dosage form and route of administration.

Can a product avoid the patent by replacing acetic acid with citric acid?

Potentially, if the product contains no acetic acid and does not satisfy the claim through an equivalent formulation element. The patent’s claim language specifically identifies acetic acid as the hydrolysis inhibitor.

Does a progestin combination automatically infringe claim 4?

No. The combination must satisfy the limitations of claim 1 and include an additional steroid with progestational activity. A combination containing ordinary estradiol rather than estradiol acetate would not satisfy the active-ingredient limitation.

Is US 6,962,908 still a current Orange Book barrier?

The patent’s ordinary term expired in 2022. It should not be treated as a current blocking patent solely on the basis of its historical listing. Current approval strategy requires review of the applicable FDA reference-product record and any other unexpired listed patents.

References

U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,962,908, pharmaceutical dosage forms comprising estradiol acetate. U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, NDA 021405. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.
21 U.S.C. § 355. (2024). New drugs.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002359758	⤷ Start Trial
Canada	2470703	⤷ Start Trial
China	1273141	⤷ Start Trial
China	1564689	⤷ Start Trial
European Patent Office	1461043	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 6,962,908